Tradestie Institutional Equity Comparison Engine · Market Close Nov 17, 2026

ATYR vs ADPT: Which Stock Is the Better Buy Now?

Deterministic 6-pillar institutional evaluation across valuation multiples, TTM & multi-year operating margins, cash generation, options IV skew, and supply-chain moat.

ATYR Captures Overall Composite Edge (34.3 SELL vs 43.2 HOLD), While ADPT Leads 4–2 on Growth & Valuation Pillars

ATYR Overall Winner 6-Pillar Tally: ATYR 2 – 4 ADPT Matrix Metrics: ATYR 3 – 5 ADPT

As of Nov 17, 2026, aTyr Pharma, Inc. (ATYR) captures the overall head-to-head institutional edge over Adaptive Biotechnologies Corporation (ADPT) on higher Unified Composite conviction (34.3/100 SELL vs. 43.2/100 HOLD) after splitting the core matrix 3–5 (led by Growth & Scale, Profitability & Quality), while ADPT wins 4–2 across the 6-pillar growth and valuation breakdown. ATYR trades at $4.96 (N/M Forward P/E, 0.0% operating margin) versus ADPT at $28.56 (N/M Forward P/E, -16.2% operating margin).

  • Composite vs. Pillar Nuance: While ADPT currently prints a higher short-term Unified Composite Score (43.2/100 HOLD vs. ATYR 34.3/100 SELL), ATYR captures the overall institutional head-to-head verdict (3–5 matrix metrics and 2–4 across the 6 pillars) due to superior fundamental profitability (0.0% vs. -16.2% operating margin) and revenue trajectory (+0.0% vs. -10.7% YoY).

Executive Snapshot Side-by-Side Composite Ratings & Technical Regime

Ask Alpha AI About ATYR vs ADPT
ATYR NASDAQ Head-to-Head Winner
aTyr Pharma, Inc. Common Stock
Biological Products, (No Disgnostic Substances)
$4.96
-5.34% 1D
Market Cap $15.6M
TTM Revenue N/A
Forward P/E N/M
Beta / 30D Vol -9.67β · 13806% Vol
Unified Composite Score
34.3 / 100 SELL
Tech 50.0 Fund 36.0 Flow 69.0 Mom 50.0
Weinstein Technical Phase Markup · Hold / add on dips
Price above SMA50, rising 50-day trend (391.4% over 20 days), RSI 58
RSI-14: 57.6 · SMA20: $4.36 · SMA50: $1.92
ADPT NASDAQ
Adaptive Biotechnologies Corporation Common Stock
Biological Products, (No Disgnostic Substances)
$28.56
+2.48% 1D
Market Cap $4.7B
TTM Revenue $298M
Forward P/E N/M
Beta / 30D Vol 1.73β · 59% Vol
Unified Composite Score
43.2 / 100 HOLD
Tech 15.0 Fund 42.0 Flow 68.0 Mom 50.0
Weinstein Technical Phase Markup · Hold / add on dips
Price above SMA50, rising 50-day trend (3.6% over 20 days), RSI 55
RSI-14: 54.6 · SMA20: $27.46 · SMA50: $27.06

6-Pillar Scorecard Institutional Category Breakdown (ATYR 2 – 4 ADPT)

Columns: Metric · ATYR · ADPT
1. Valuation Multiples ADPT
Forward P/E N/M N/M
Trailing P/E N/M N/M
PEG Ratio N/M N/M
EV / Revenue N/M 16.9x
2. Growth & Scale ATYR
Revenue Growth (YoY) +0.0% -10.7%
Earnings Growth (YoY) +0.0% -70.1%
TTM Revenue (USD) N/A $298M
Market Cap $15.6M $4.7B
3. Profitability & Quality ATYR
Gross Margin N/A 46.2%
Operating Margin 0.0% -16.2%
Net Profit Margin 0.0% -23.7%
Return on Equity (ROE) -93.7% -36.4%
4. Balance Sheet & Cash Flow ADPT
Cash Generation (TTM) N/A -$8.8M
Cash Flow Margin N/A -3.0%
Net Cash / Leverage $4.9M Net Cash $333M Net Debt (2.32x D/E)
Dividend Yield None (0.00%) None (0.00%)
5. Options & Positioning ADPT
Options Structure Phase UNCLASSIFIED BREAKOUT
Current IV / %ile 154.5% (36th %ile) 78.0% (36th %ile)
Put/Call OI Skew N/A 0.01x (Call-Skewed)
OBV Trend / Tech Phase NEUTRAL · Markup ACCUMULATION · Markup
6. R&D & Supply-Chain Moat ADPT
OpEx & R&D Intensity N/A 62.4% of Rev ($186M)
90D R&D Disclosures 0 papers 0 papers
Competitive Moat Cyclical / Execution-Driven Positioning Cyclical / Execution-Driven Positioning
Supply-Chain Role Biotechnology Operator Diagnostics & Research Operator

Core Matrix Head-to-Head Valuation, Margin, Cash Flow & Risk Table

Core Matrix Wins: ATYR (3) vs ADPT (5)
Institutional Metric ATYR ADPT Criterion Row Edge
Market Capitalization
Scale
$15.6M $4.7B Larger Scale ADPT
Trailing P/E Ratio
Valuation
N/M N/M Lower Multiple Tie
Forward P/E Ratio
Valuation
N/M N/M Lower Multiple Tie
Revenue Growth (YoY)
Growth
+0.0% -10.7% Higher Growth ATYR
Operating Margin (TTM)
Profitability
0.0% -16.2% Higher Margin ATYR
Net Profit Margin
Profitability
0.0% -23.7% Higher Margin ATYR
Return on Equity (ROE)
Capital Efficiency
-93.7% -36.4% Higher ROE ADPT
52-Week Range Position
Momentum
62% ($0–$8) 82% ($12–$32) Stronger Trend ADPT
Beta / 30D Volatility
Risk Regime
-9.67β · 13806% Vol 1.73β · 59% Vol Lower Realized Risk ADPT
Unified Institutional Score
Composite Signal
34.3 / 100 (SELL) 43.2 / 100 (HOLD) Higher Composite ADPT
Trailing 12M Revenue (USD)
Operating Scale
N/A $298M FX-Normalized USD Scale
Gross Profit Margin (TTM)
Unit Pricing Power
N/A 46.2% Higher Margin Quality
PEG Ratio & EV / Revenue
Growth-Adjusted Valuation
N/M PEG · N/M EV/Rev N/M PEG · 16.9x EV/Rev Lower Multiple Valuation
Cash Flow & Balance Sheet
Capital Self-Funding
N/A ($4.9M Net Cash) -$8.8M ($333M Net Debt (2.32x D/E)) Higher Cash / Net Cash Solvency

Momentum Normalized Relative Price Performance (1M · 3M · 6M · 1Y)

1M Horizon ATYR +2769.51 pp
ATYR: +2788.76% · ADPT: +19.25%
3M Horizon ATYR +818.89 pp
ATYR: +830.93% · ADPT: +12.04%
6M Horizon ATYR +806.55 pp
ATYR: +926.92% · ADPT: +120.37%
1Y Horizon ATYR +456.15 pp
ATYR: +558.7% · ADPT: +102.55%

Financial Trajectory Multi-Year Annual Revenue & Operating Margin Trajectory (USD)

Split-Invariant USD Revenue & Operating Margin (%)
Period ATYR Revenue ADPT Revenue ATYR Op. Margin ADPT Op. Margin Margin Leader
FY2018 N/A $60M N/A -89.4% ADPT
FY2019 $0M $90M -5445.0% -92.1% ADPT
FY2020 $10M $100M -152.2% -155.3% ATYR
FY2021 N/A $150M N/A -135.4% ADPT
FY2022 $10M $190M -446.8% -108.0% ADPT
FY2023 $0M $170M -15557.8% -133.3% ADPT
FY2024 $0M $180M -28899.6% -90.8% ADPT
FY2025 $0M $280M -40856.3% -20.6% ADPT

Options Positioning Implied Volatility, Put/Call Skew & Dealer Gamma Corridor

Live Options Phase Tracker
ATYR UNCLASSIFIED
0d in phase · OBV NEUTRAL
Current IV 154.5%
IV Percentile 36th %ile
Put/Call OI Skew N/A
IV Regime Balanced (25th–60th %ile)
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
Net Delta Signal BULLISH
OBV Flow NEUTRAL
Exact ATYR Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro. Unlock 14-Day Free Trial →
ADPT BREAKOUT
70d in phase · OBV ACCUMULATION
Current IV 78.0%
IV Percentile 36th %ile
Put/Call OI Skew 0.01x (Call-Skewed)
IV Regime Balanced (25th–60th %ile)
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
Net Delta Signal BULLISH
OBV Flow ACCUMULATION
Exact ADPT Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro. Unlock 14-Day Free Trial →

Moat & R&D Supply-Chain Positioning, Bottleneck Moat & R&D Velocity

Corporate R&D & Foundry Leaderboard
ATYR Moat Profile Cyclical / Execution-Driven Positioning
Biotechnology Operator
Competes within the Biotechnology value chain with $15.6M market capitalization and 0.0% operating margin.
OpEx & R&D Reinvestment N/A
90D Engineering Disclosures 0 Published
ADPT Moat Profile Cyclical / Execution-Driven Positioning
Diagnostics & Research Operator
Competes within the Diagnostics & Research value chain with $4.7B market capitalization and -16.2% operating margin.
OpEx & R&D Reinvestment 62.4% of Rev ($186M)
90D Engineering Disclosures 0 Published

Investor FAQ ATYR vs ADPT Key Questions & Quantitative Answers

As of Nov 17, 2026, aTyr Pharma, Inc. (ATYR) captures the overall head-to-head institutional edge over Adaptive Biotechnologies Corporation (ADPT) on higher Unified Composite conviction (34.3/100 SELL vs. 43.2/100 HOLD) after splitting the core matrix 3–5 (led by Growth & Scale, Profitability & Quality), while ADPT wins 4–2 across the 6-pillar growth and valuation breakdown. ATYR trades at $4.96 (N/M Forward P/E, 0.0% operating margin) versus ADPT at $28.56 (N/M Forward P/E, -16.2% operating margin). Composite vs. Pillar Nuance: While ADPT currently prints a higher short-term Unified Composite Score (43.2/100 HOLD vs. ATYR 34.3/100 SELL), ATYR captures the overall institutional head-to-head verdict (3–5 matrix metrics and 2–4 across the 6 pillars) due to superior fundamental profitability (0.0% vs. -16.2% operating margin) and revenue trajectory (+0.0% vs. -10.7% YoY).

ATYR leads the Growth & Scale pillar: ATYR posts +0.0% YoY revenue growth and +0.0% YoY earnings growth on N/A TTM revenue (N/A gross margin, 0.0% operating margin), compared with ADPT at -10.7% YoY revenue growth and -70.1% YoY earnings growth on $298M TTM revenue (46.2% gross margin, -16.2% operating margin). Across the 8-period historical trajectory (FY2018 to FY2025), ATYR cumulative revenue shifted +0.0% while ADPT shifted +366.7%. In operating R&D and SG&A reinvestment, ATYR deploys N/A (0 90-day corporate R&D disclosures) versus 62.4% of Rev ($186M) (0 disclosures) for ADPT.

ADPT screens cheaper on headline valuation multiples. ATYR trades at N/M Forward P/E, N/M Trailing P/E, N/M PEG, and N/M EV/Revenue (unreported cash flow margin), whereas ADPT trades at N/M Forward P/E, N/M Trailing P/E, N/M PEG, and 16.9x EV/Revenue (-3.0% FCF margin). Multiples above 150x or negative earnings denominators are marked N/M to avoid distorted accounting comparisons; weigh lower Forward P/E and PEG against ATYR (-93.7% ROE) versus ADPT (-36.4% ROE) capital efficiency.

In options market volatility and institutional positioning, ATYR carries 154.5% implied volatility (36th %ile, Balanced (25th–60th %ile)), unclassified Put/Call open interest, NEUTRAL on-balance volume, and sits in an UNCLASSIFIED options structure phase (-9.67β · 13806% Vol realized risk). By comparison, ADPT carries 78.0% implied volatility (36th %ile, Balanced (25th–60th %ile)), a 0.01x (Call-Skewed) Put/Call open-interest ratio, ACCUMULATION on-balance volume, and sits in a BREAKOUT options structure phase (1.73β · 59% Vol realized risk).

Cross-Compare 1-Click Peer Rivalries & Single-Stock Research

Launch Custom Ticker Comparison →

Powered by Tradestie Institutional Equity Comparison Engine & standardized corporate financial telemetry. Market close as of Nov 17, 2026. For educational research only; not investment advice.